Medpace (NASDAQ:MEDP) CEO August Troendle Sells 13,995 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 13,995 shares of Medpace stock in a transaction on Friday, August 21st. The stock was sold at an average price of $624.45, for a total transaction of $8,739,177.75. Following the sale, the chief executive officer directly owned 547,200 shares of the company’s stock, valued at $341,699,040. This represents a 2.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Medpace Stock Performance

Shares of Medpace stock opened at $614.06 on Wednesday. The firm has a fifty day moving average of $556.26 and a two-hundred day moving average of $492.77. The stock has a market capitalization of $17.14 billion, a price-to-earnings ratio of 35.99, a PEG ratio of 2.77 and a beta of 1.15. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue was up 17.2% on a year-over-year basis. During the same period last year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Medpace

Institutional investors and hedge funds have recently modified their holdings of the company. California State Teachers Retirement System boosted its holdings in shares of Medpace by 53,619.6% during the 2nd quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock worth $7,408,778,000 after buying an additional 13,963,607 shares during the period. BlackRock Inc. bought a new position in Medpace in the 2nd quarter valued at about $1,323,047,000. AQR Capital Management LLC lifted its position in Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after acquiring an additional 324,293 shares during the last quarter. Wasatch Advisors LP lifted its position in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after acquiring an additional 24,625 shares during the period. 77.98% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on MEDP. Robert W. Baird raised their target price on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Truist Financial upped their price target on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Mizuho increased their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. TD Cowen raised their price objective on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Finally, BMO Capital Markets raised their price objective on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $584.18.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace’s latest quarterly results were strong: earnings of $4.25 per share exceeded the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, ahead of expectations. Management’s fiscal 2026 EPS guidance is $17.25–$17.95. Institutional ownership is also high at approximately 78%, with several large investors adding positions.
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the figures show no measurable short position, they provide little indication of near-term buying or selling pressure.
• Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” with an average price target of $584.18, below recent trading levels. BMO Capital Markets raised its target to $600 while maintaining a market-perform rating, and Weiss Ratings upgraded the stock to “Buy.”
• Negative Sentiment: Multiple company insiders recently sold shares. CEO August J. Troendle sold 13,995 shares for approximately $8.74 million on August 21 and another 1,983 shares for about $1.23 million on August 24. CFO Kevin Brady sold 3,400 shares worth roughly $2.13 million, reducing his ownership by 20.95%. Additional director sales were also reported. Although executives retain significant holdings, the concentration of selling can weigh on investor confidence.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.